M. K. Proteins Limited Schedules Board Meeting on May 29, 2026 to Consider Q4FY26 Audited Financial Results

M. K. Proteins Limited has notified the stock exchanges of a forthcoming Board of Directors meeting scheduled for Friday, May 29, 2026. The intimation, dated May 18, 2026, was filed pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was addressed to both the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited.

Board Meeting Agenda

The Board meeting has been convened to consider and approve several key business items. The following matters are scheduled to be taken up at the meeting:

Agenda Item:	Details
Financial Results:	Audited Financial Results for the quarter and year ended March 31, 2026
Cost Auditor Re-appointment:	M/s. K. K. Sinha & Associates, Cost Accountants (Firm Regn. No. 100279) for FY2026-27
Internal Auditor Re-appointment:	M/s. Jayant Bansal & Co., Chartered Accountants for FY2026-27
Other Business:	Any other items with the permission of the Chairman

Trading Window Closure

In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct for Prevention of Insider Trading, the Trading Window for trading in equity shares of M. K. Proteins Limited will remain closed until 48 hours after the declaration of the aforesaid financial results, following which it will reopen accordingly.

The intimation was signed by Neha Aggarwal, Company Secretary & Compliance Officer, on behalf of M. K. Proteins Limited, on May 18, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.51%	+0.80%	-5.62%	-22.22%	-31.71%	+472.73%

MK Proteins Limited has submitted its quarterly compliance certificate to stock exchanges for the quarter ended March 31, 2026, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulation, 2018.

Regulatory Compliance Filing

The company filed the mandatory certificate with both Bombay Stock Exchange Limited and National Stock Exchange of India Limited on April 10, 2026. The submission was signed by Managing Director Parmod Kumar (DIN: 00126965) and addressed the compliance requirements under Regulation 74(5) of SEBI regulations.

Filing Details:	Information
Quarter Ended:	March 31, 2026
Filing Date:	April 10, 2026
Regulation:	SEBI Regulation 74(5)
Signatory:	Parmod Kumar, Managing Director

Share Transfer Agent Confirmation

Bigshare Services Private Limited, the company's registrar and share transfer agent, issued a certificate dated April 4, 2026, confirming the non-applicability of certain SEBI regulations. The RTA holds SEBI Registration No INR000001385 and serves as the official registrar for MK Proteins Limited.

The certificate specifically addressed Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018, which was previously known as Regulation 54 of SEBI (Depository and Participant) Regulations, 1996.

Dematerialisation Status

According to the RTA's certificate, the regulation was not applicable to MK Proteins Limited during Q4FY26 due to specific operational circumstances. The key findings include:

Entire shareholding of the company remains in dematerialised form
No requests received from shareholders for rematerialisation during the quarter
No requests received from shareholders for dematerialisation during the quarter
Complete digital share management maintained throughout Q4FY26

Share Status Summary:	Details
Share Form:	100% Dematerialised
Rematerialisation Requests:	None
Dematerialisation Requests:	None
Quarter Period:	Q4FY26

Corporate Information

MK Proteins Limited operates from its registered office at Naraingarh Road, Village Garnala, Ambala City, Haryana. The company trades on stock exchanges under scrip code 543919 on BSE and symbol MKPL on NSE. The filing demonstrates the company's commitment to maintaining regulatory compliance and transparent shareholder communication.